Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.

Antimicrobial agents and chemotherapy - 11 Jan 2016

Cheng Guofeng, Tian Yang, Doehle Brian, Peng Betty, Corsa Amoreena, Lee Yu-Jen, Gong Ruoyu, Yu Mei, Han Bin, Xu Simin, Dvory-Sobol Hadas, Perron Michel, Xu Yili, Mo Hongmei, Pagratis Nikos, Link John O, Delaney William

Abstract excerpt

Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activity in combination with other anti-HCV agents. LDV has picomolar antiviral activity against genotype 1a and genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Synergism

Share to Fluorenes

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26824950
DOI: 10.1128/AAC.02524-15
PMCID: PMC4775926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.PMID 26824950Read ↗

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.Semantic proximity Read ↗

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.Semantic proximity Read ↗

Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.Semantic proximity Read ↗

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.Semantic proximity Read ↗

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.Semantic proximity Read ↗

Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.Semantic proximity Read ↗

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.Semantic proximity Read ↗

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Semantic proximity Read ↗

All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.Semantic proximity Read ↗

Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.